Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Aligos Therapeutics, Inc. ALGS

Healthcare  —  Biotechnology
5.51 (0.04) (0.72%) as of 25 Sep
Market cap
$32.6M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Aligos Therapeutics, Inc. (ALGS) Business Profile

Updated before January 2025

Company Overview

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biopharmaceutical company dedicated to the development of targeted therapies for viral and liver diseases. Founded in 2018 and headquartered in South San Francisco, California, Aligos leverages its expertise in medicinal chemistry, virology, and liver disease biology to create innovative treatments. The company was co-founded by Dr. Lawrence Blatt, a seasoned leader in the biopharmaceutical industry, who also serves as the Chairman and CEO. Aligos’s leadership team comprises experienced professionals with extensive backgrounds in drug discovery, development, and commercialization, positioning the company as a leader in its niche.

Core Business Segments

Antiviral Therapies

Aligos focuses on developing therapies for chronic hepatitis B virus (CHB) infection, a significant global health challenge. The company’s lead product candidate, ALG-000184, is a small molecule capsid assembly modulator (CAM) designed to inhibit HBV replication. Another key candidate, ALG-125755, is an antisense oligonucleotide (ASO) targeting HBV RNA to reduce viral protein production.

Liver Disease Therapies

In addition to antiviral therapies, Aligos is advancing treatments for nonalcoholic steatohepatitis (NASH), a chronic liver disease with limited therapeutic options. The company’s NASH pipeline includes ALG-055009, a thyroid hormone receptor beta (THR-β) agonist aimed at reducing liver fat and improving liver health.

Platform Technologies

Aligos employs proprietary platform technologies to accelerate drug discovery and development. These include advanced medicinal chemistry techniques and high-throughput screening methods to identify and optimize novel compounds.

Business Model

Aligos Therapeutics operates as a research-driven biopharmaceutical company. Its business model revolves around the discovery, development, and commercialization of innovative therapies. The company generates revenue through partnerships, licensing agreements, and potential future product sales. Aligos collaborates with academic institutions and industry partners to leverage complementary expertise and resources, enabling it to advance its pipeline efficiently.

Strategic Direction

Aligos aims to become a leader in the treatment of viral and liver diseases. The company’s strategic priorities include:

  • Advancing Clinical Programs: Aligos is focused on progressing its lead candidates, ALG-000184 and ALG-055009, through clinical trials to demonstrate safety and efficacy.
  • Expanding the Pipeline: The company is actively exploring new therapeutic targets and indications to broaden its portfolio.
  • Sustainability Goals: Aligos is committed to sustainable practices in its operations and aims to minimize its environmental footprint.
  • Global Reach: The company seeks to expand its presence in international markets, particularly in regions with high prevalence of HBV and NASH.

Competitive Landscape

Aligos operates in a competitive biopharmaceutical landscape, facing competition from both established companies and emerging startups. Key competitors include:

  • Gilead Sciences: A leader in antiviral therapies, particularly for HBV and HIV.
  • Arrowhead Pharmaceuticals: Focused on RNA interference (RNAi) therapies for liver diseases.
  • Intercept Pharmaceuticals: Specializes in treatments for NASH and other liver conditions.
  • Assembly Biosciences: Develops novel therapies for HBV and other infectious diseases.

Despite the competition, Aligos differentiates itself through its innovative platform technologies and targeted approach to drug development.

Risk Factors

Aligos faces several risks that could impact its business:

  • Clinical Trial Risks: The success of Aligos’s pipeline depends on the outcomes of clinical trials, which are inherently uncertain.
  • Regulatory Challenges: Obtaining regulatory approval for new therapies is a complex and time-consuming process.
  • Market Dependence: The company’s revenue prospects are tied to the commercial success of its lead candidates.
  • Supply Chain Disruptions: Aligos relies on third-party manufacturers and suppliers, making it vulnerable to supply chain issues.
  • Competition: Intense competition in the biopharmaceutical sector could limit market opportunities for Aligos’s products.

Recent Developments

Aligos has made significant progress in its clinical programs and corporate strategy:

  • Clinical Milestones: The company recently announced positive interim data from Phase 1 trials of ALG-000184, demonstrating its potential as a best-in-class CAM for HBV.
  • Partnerships: Aligos entered into a collaboration with a leading pharmaceutical company to co-develop novel therapies for liver diseases.
  • Corporate Initiatives: The company implemented cost-saving measures to extend its cash runway and support ongoing R&D activities.

Investment Considerations

Strengths

  • Innovative Pipeline: Aligos’s focus on HBV and NASH addresses significant unmet medical needs.
  • Experienced Leadership: The company’s management team has a proven track record in drug development.
  • Proprietary Technologies: Aligos’s platform technologies provide a competitive edge in drug discovery.

Risks

  • Early-Stage Company: As a clinical-stage company, Aligos has no approved products and relies on external funding.
  • Regulatory and Clinical Risks: The success of its pipeline depends on favorable clinical and regulatory outcomes.
  • Market Competition: Aligos faces competition from established players with greater resources.

Conclusion

Aligos Therapeutics, Inc. is well-positioned to address critical unmet needs in viral and liver diseases. With a robust pipeline, innovative technologies, and a dedicated leadership team, the company has significant growth potential. However, investors should consider the inherent risks associated with early-stage biopharmaceutical companies. As Aligos advances its clinical programs and explores new opportunities, it remains a promising player in the biopharmaceutical industry.